- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07439666
NEUROCUPLE™ como alternativa a los opioides tras la artroplastia total de rodilla
El papel de NEUROCUPLE™ como alternativa a los opioides en pacientes tras artroplastia total de rodilla
The goal of this clinical trial is to learn if the NEUROCUPLE device can reduce pain and opioid use after primary unilateral total knee arthroplasty (TKA) in adults.
The main questions it aims to answer are:
- Does the NEUROCUPLE device reduce postoperative pain at rest during the first 24 hours after TKA?
- Does the NEUROCUPLE device reduce opioid consumption during the first 24 hours after TKA?
Researchers will compare the NEUROCUPLE device to a placebo device (identical in appearance but inactive) to see if the device reduces pain and opioid use after surgery.
Participants will:
- Apply the NEUROCUPLE device or placebo device for 7 days following surgery
- Have their pain and opioid use monitored through clinical records and patient reporting
- Report pain at rest and during movement on postoperative Days 2 and 7
- Be assessed for nausea, vomiting, device-related side effects, length of hospital stay, and overall satisfaction
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Tipo de estudio
Inscripción (Estimado)
Fase
- No aplica
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Jacques E. Chelly, MD, PhD, MBA
- Número de teléfono: (412)623-6904
- Correo electrónico: ChelJE@anes.upmc.edu
Copia de seguridad de contactos de estudio
- Nombre: Heather Margonari, DNP, FNP, BC
- Número de teléfono: 412-623-1914
- Correo electrónico: margonarih@upmc.edu
Ubicaciones de estudio
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Estados Unidos, 15232
- UPMC Shadyside Hospital
-
Investigador principal:
- Jacques E. Chelly, MD, PhD, MBA
-
Contacto:
- Heather Margonari,, DNP, FNP-BC
- Número de teléfono: 412-623-1914
- Correo electrónico: margonarih@upmc.edu
-
Contacto:
- Sarah Warner
- Correo electrónico: warners3@upmc.edu
-
Pittsburgh, Pennsylvania, Estados Unidos, 15237
- UPMC Passavant Hospital
-
Investigador principal:
- Jacques E. Chelly, MD, PhD, MBA
-
Pittsburgh, Pennsylvania, Estados Unidos, 15146
- UPMC East Hospital
-
Investigador principal:
- Jacques E. Chelly, MD, PhD, MBA
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- >18 years of age
- Scheduled for elective primary unilateral TKA
Exclusion Criteria:
- Children (<18 yr.)
- Pregnant women
- Active alcoholism (defined as daily use of more than 1 liter of wine and /or 3 or more shots of hard liquor) or drug abuse (defined as daily use of illicit drugs)
- Severe chronic pain condition that requires daily preoperative opioid dependence
- Other concomitant surgery being performed in addition to TKA
- Patients undergoing bilateral TKA
- Patients undergoing knee replacement revision
- Patients with limited mobility (in a wheelchair or requiring a walker)
- Patients who are not returning home after surgery
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Doble
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: NEUROCUPLE™ Group
This arm of subjects will receive the active NEUROCUPLE™ patch to wear for 7 days following their TKA surgery. |
nCAP Medical has developed an effective, safe, non-opioid alternative, the NEUROCUPLE™ device, based on an innovative nanotechnology to reduce surgical pain and facilitate functional recovery while reducing opioid prescriptions, opioid-related adverse events and reducing the cost of care in millions of Americans undergoing TKA each year. The patch will be worn for 7-days Participants in both arms will receive approved Enhanced Recovery After Surgery (ERAS) multimodal care, including preoperative education and optimization, intraoperative minimally invasive techniques and multimodal analgesia, and postoperative early mobilization, early nutrition, pain control, and monitoring for complications |
|
Comparador falso: Sham Group
This arm of subjects will receive the placebo (non-active, sham) patch to wear for 7 days following their TKA surgery. |
Participants in both arms will receive approved Enhanced Recovery After Surgery (ERAS) multimodal care, including preoperative education and optimization, intraoperative minimally invasive techniques and multimodal analgesia, and postoperative early mobilization, early nutrition, pain control, and monitoring for complications Non-active placebo patch visually identical to NEUROCUPLE™ worn for 7 days following total knee arthroplasty. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Opioid Consumption
Periodo de tiempo: 0- 24 hours post-surgery
|
Total opioid consumption, expressed in milligrams of morphine equivalents (MME), during the first 24 hours following surgery. Opioid use will be calculated using all available data sources, including in-hospital medication administration records and, when applicable, the state Prescription Drug Monitoring Program (PDMP). MME values will be compared between the NEUROCUPLE™ patch group and the placebo patch group. Lower MME values indicate reduced opioid requirements and may reflect improved postoperative pain control, while higher MME values suggest increased opioid use and potentially greater pain or slower recovery. |
0- 24 hours post-surgery
|
|
Pain at Rest Using Numerical Rating Scale (NRS)
Periodo de tiempo: 0-24 hours post-surgery
|
Pain at rest during the first 24 hours after surgery will be assessed using a Numerical Rating Scale (NRS; 0 = no pain, 10 = worst pain) and compared between the NEUROCUPLE™ patch group and the placebo patch group. Higher scores indicate worse pain |
0-24 hours post-surgery
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Pain Scores Using Numerical Rating Scale (NRS) at Rest and during Movement
Periodo de tiempo: Post-operative at Day 2 and Day 7
|
Pain will be assessed using a Numerical Rating Scale (0 = no pain, 10 = worst pain) at rest and during movement on postoperative Days 2 and 7. Higher scores indicate worse pain. |
Post-operative at Day 2 and Day 7
|
|
Patient Satisfaction
Periodo de tiempo: at Post-operative Day 7
|
Patient satisfaction with recovery and device use will be assessed on postoperative Day 7 using standardized questionnaires. Scores range from 0 to 10, where 0 indicates the lowest level of satisfaction and 10 indicates the highest. |
at Post-operative Day 7
|
|
Opioid Consumption
Periodo de tiempo: Post-Operative Day 0- Day 7
|
Total opioid consumption, expressed in milligrams of morphine equivalents (MME), will be recorded over the 7-day postoperative period. Opioid use will be calculated using all available data sources, including in-hospital medication administration records and the state Prescription Drug Monitoring Program (PDMP) when applicable. MME values will be compared between the NEUROCUPLE™ patch group and the placebo patch group. Lower MME values indicate reduced opioid requirements and may reflect improved postoperative pain control, whereas higher MME values suggest increased opioid use and potentially greater pain or slower recovery. |
Post-Operative Day 0- Day 7
|
|
Postoperative Adverse Events and Device-Related Side Effects
Periodo de tiempo: Postoperative Days 0-7
|
The incidence of postoperative adverse events, including any events determined to be related to the study device, will be recorded and compared between the treatment groups during the 7-day postoperative period. Lower incidence rates indicate fewer complications and a more favorable safety profile, whereas higher incidence rates suggest increased complications, potential device-related issues, or a less favorable safety profile. |
Postoperative Days 0-7
|
|
Incidence of postoperative nausea and/or vomiting (yes/no)
Periodo de tiempo: Postoperative Days 0-7
|
Incidence and severity of postoperative nausea and vomiting will be recorded over the 7-day postoperative period as (yes/no) and compared between groups. |
Postoperative Days 0-7
|
|
Postoperative Length of Stay
Periodo de tiempo: From the date of surgery until hospital discharge (within the 7-day study period)
|
Length of hospital stay, defined as the number of days from the date of surgery to the date of hospital discharge, will be recorded and compared between groups. Lower length of stay values indicate faster recovery, fewer complications, and earlier readiness for discharge. Higher length of stay values suggest slower recovery, increased complications, or higher postoperative symptom burden. |
From the date of surgery until hospital discharge (within the 7-day study period)
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Jacques E. Chelly, MD, PhD, MBA, University of Pittsburgh / UPMC
- Director de estudio: Alisha Maslanka, BS, CCRC, University of Pittsburgh / UPMC
- Director de estudio: Heather Margonari,, University of Pittsburgh / UPMC
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Estimado)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Dolor
- Manifestaciones neurológicas
- Complicaciones Postoperatorias
- Procesos Patológicos
- Condiciones Patológicas, Signos y Síntomas
- Signos y síntomas
- Dolor Postoperatorio
- Administración de Servicios de Salud
- Calidad, acceso y evaluación de la atención médica
- Procedimientos quirúrgicos, operativo
- Calidad de la atención médica
- Indicadores de calidad, atención médica
- Atención perioperatoria
- Estándar de cuidado
- Recuperación mejorada después de la cirugía
Otros números de identificación del estudio
- STUDY25120065
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
producto fabricado y exportado desde los EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .